{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:45Z","timestamp":1792552305780,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40265-025-02259-w","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T11:13:59Z","timestamp":1765192439000},"page":"385-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rilzabrutinib: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"11","key":"2259_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/1750743X.2025.2545170","volume":"17","author":"DJ Kuter","year":"2025","unstructured":"Kuter DJ, Ghanima W. Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. Immunotherapy. 2025;17(11):767\u201382.","journal-title":"Immunotherapy"},{"key":"2259_CR2","unstructured":"Sanofi. Sanofi completes Principia Biopharma Inc. acquisition [media release]. 28 Sep 2020."},{"key":"2259_CR3","unstructured":"Sanofi. Sanofi\u2019s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia [media release]. 29 Aug 2025."},{"key":"2259_CR4","unstructured":"Genzyme Corporation. WAYRILZ\u2122 (rilzabrutinib) tablets: US prescribing information. 2025. https:\/\/products.sanofi.us\/wayrilz\/wayrilz.pdf. Accessed 3 Sep 2025."},{"key":"2259_CR5","unstructured":"Sanofi. Sanofi\u2019s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia [media release]. 17 Oct 2025. https:\/\/www.sanofi.com."},{"issue":"7","key":"2259_CR6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","volume":"206","author":"CL Langrish","year":"2021","unstructured":"Langrish CL, Bradshaw JM, Francesco MR, et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease. J Immunol. 2021;206(7):1454\u201368.","journal-title":"J Immunol"},{"issue":"21","key":"2259_CR7","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1182\/bloodadvances.2024012713","volume":"8","author":"CW Smith","year":"2024","unstructured":"Smith CW, Campos J, Brown HC, et al. Selective Btk inhibition by PRN1008\/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice. Blood Adv. 2024;8(21):5557\u201370.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2259_CR8","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1182\/blood-2024-200182","volume":"144","author":"A Daak","year":"2024","unstructured":"Daak A, Light DR, Abdulla F, et al. Bruton tyrosine kinase inhibitor rilzabrutinib reduces vaso-occlusion and markers of inflammation and adhesion in transgenic mice with sickle cell disease [abstract]. Blood. 2024;144(Suppl 1):2482.","journal-title":"Blood"},{"key":"2259_CR9","doi-asserted-by":"publisher","first-page":"A7754","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A7754","volume":"211","author":"ME Wechsler","year":"2025","unstructured":"Wechsler ME, Maspero J, Pavord ID, et al. RNA Sequencing analysis of nasal brushings from participants administered rilzabrutinib 1200 mg demonstrated an impact on multiple pathways relevant for asthma [abstract no. A7754]. Am J Respir Crit Care Med. 2025;211:A7754.","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 68","key":"2259_CR10","first-page":"OA1077","volume":"64","author":"KT Shade","year":"2024","unstructured":"Shade KT, Mukai S, Hicks A. Rilzabrutinib, a potent and selective Bruton\u2019s tyrosine kinase inhibitor, suppresses reactive oxygen species production and CD11b activation in human eosinophils [abstract no. OA1077]. Eur Respir J. 2024;64(Suppl 68):OA1077.","journal-title":"Eur Respir J"},{"issue":"24","key":"2259_CR11","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1182\/blood.2024027336","volume":"145","author":"DJ Kuter","year":"2025","unstructured":"Kuter DJ, Ghanima W, Cooper N, et al. Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. Blood. 2025;145(24):2914\u201326.","journal-title":"Blood"},{"issue":"3","key":"2259_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ajh.27539","volume":"100","author":"N Cooper","year":"2025","unstructured":"Cooper N, Jansen AJG, Bird R, et al. Efficacy and safety results with rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with immune thrombocytopenia: phase 2 part B study. Am J Hematol. 2025;100(3):439\u201349.","journal-title":"Am J Hematol"},{"issue":"15","key":"2259_CR13","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","volume":"386","author":"DJ Kuter","year":"2022","unstructured":"Kuter DJ, Efraim M, Mayer J, et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med. 2022;386(15):1421\u201331.","journal-title":"N Engl J Med"},{"issue":"7","key":"2259_CR14","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/bloodadvances.2023012044","volume":"8","author":"DJ Kuter","year":"2024","unstructured":"Kuter DJ, Mayer J, Efraim M, et al. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia. Blood Adv. 2024;8(7):1715\u201324.","journal-title":"Blood Adv"},{"issue":"7","key":"2259_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamadermatol.2025.0733","volume":"161","author":"A Gim\u00e9nez-Arnau","year":"2025","unstructured":"Gim\u00e9nez-Arnau A, Ferrucci S, Ben-Shoshan M, et al. Rilzabrutinib in antihistamine-refractory chronic spontaneous urticaria: the RILECSU phase 2 randomized clinical trial. JAMA Dermatol. 2025;161(7):679\u201387.","journal-title":"JAMA Dermatol"},{"issue":"Suppl 1","key":"2259_CR16","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1182\/blood-2024-200325","volume":"144","author":"N Cooper","year":"2024","unstructured":"Cooper N, Kuter DJ, Frederiksen H, et al. Part A efficacy and safety of oral Bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in patients with warm autoimmune hemolytic anemia (wAIHA): multicenter, open-label, phase 2b study [abstract]. Blood. 2024;144(Suppl 1):3836\u20137.","journal-title":"Blood"},{"key":"2259_CR17","doi-asserted-by":"publisher","first-page":"A1298","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1298","volume":"211","author":"WW Busse","year":"2025","unstructured":"Busse WW, Maspero JF, Pavord ID, et al. Reduction in the use of rescue medication for asthma symptom relief with rilzabrutinib: results from a phase 2 study [abstract no. A1298]. Am J Respir Crit Care Med. 2025;211:A1298.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02259-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02259-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02259-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:35:35Z","timestamp":1772764535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02259-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2259"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02259-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}